News: Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

65.74USD
11 Jul 2014
Price Change (% chg)

$-0.56 (-0.84%)
Prev Close
$66.30
Open
$67.00
Day's High
$67.10
Day's Low
$65.42
Volume
390,824
Avg. Vol
879,697
52-wk High
$82.00
52-wk Low
$36.18

Search Stocks
Select another date:

Thu, Mar 6 2014

FDA approves Endo International's testosterone drug

- Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism.

UPDATE 1-FDA approves Endo International's testosterone drug

March 6 - Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism.

FDA approves Endo Health's testosterone drug

March 6 - Endo Health Solutions Inc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone drug, Aveed, to treat male hypogonadism.

Endo to pay $193 million over Lidoderm marketing

NEW YORK - Endo Health Solutions Inc will pay $193 million to resolve civil and criminal allegations of unlawful marketing of the pain treatment Lidoderm, the U.S. Justice Department and New York Attorney General Eric Schneiderman said Friday.

Endo to pay $193 million over Lidoderm marketing

NEW YORK - Endo Health Solutions Inc will pay $193 million to resolve civil and criminal allegations of unlawful marketing of the pain treatment Lidoderm, the Justice Department and New York Attorney General Eric Schneiderman said Friday.

UPDATE 1-Endo to pay $193 million over Lidoderm marketing

NEW YORK, Feb 21 - Endo Health Solutions Inc will pay $193 million to resolve civil and criminal allegations of unlawful marketing of the pain treatment Lidoderm, the U.S. Justice Department and New York Attorney General Eric Schneiderman said Friday.

UPDATE 1-Endo to pay $193 million over Lidoderm marketing

NEW YORK, Feb 21 - Endo Health Solutions Inc agreed to pay $193 million to resolve civil and criminal allegations of unlawful marketing of the drug Lidoderm, the U.S. Justice Department and New York state Attorney General Eric Schneiderman announced on Friday.

BRIEF-Endo to pay $173 million over Lidoderm marketing

NEW YORK, Feb 21 - Endo Health Solutions Inc agreed to pay $173 million to U.S. state and federal authorities to resolve allegations of unlawful marketing of the drug Lidoderm, New York Attorney General Eric Schneiderman said in a statement.

NuPathe accepts Teva's takeover offer, ends deal with Endo

Jan 21 - NuPathe Inc said it terminated its takeover deal with Endo Health Solutions Inc and accepted an offer from Israel's Teva Pharmaceutical Industries Ltd .

Select another date:
Search Stocks